Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -200% Improvement Relative Risk ICU admission 67% Hospitalization time 10% c19hcq.org Uyaroğlu et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? PSM retrospective 84 patients in Turkey (March - September 2020) Study compares with favipiravir, results vs. placebo may differ Study underpowered for serious outcomes Uyaroğlu et al., Acta Medica, doi:10.32552/2022.ActaMedica.719 Favors HCQ Favors favipiravir
Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Single-center, Retrospective, Propensity Score-matched Study
Uyaroğlu et al., Acta Medica, doi:10.32552/2022.ActaMedica.719
Uyaroğlu et al., Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with.., Acta Medica, doi:10.32552/2022.ActaMedica.719
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective 260 late stage hospitalized COVID-19 pneumonia patients in Turkey, showing no significant difference between favipiravir and HCQ.
risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 42 (2.4%), control 0 of 42 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 42 (0.0%), control 1 of 42 (2.4%), NNT 42, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 9.8% lower, relative time 0.90, p = 0.90, treatment 42, control 42.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Uyaroğlu et al., 17 Mar 2022, retrospective, propensity score matching, Turkey, peer-reviewed, 6 authors, study period 20 March, 2020 - 30 September, 2020, this trial compares with another treatment - results may be better when compared to placebo.
Contact: oguzuyaroglu@hotmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Acta Medica 2022; 53(1): 73-82 acta medica ORIGINAL ARTICLE Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Singlecenter, Retrospective, Propensity Score-matched Study Oğuz Abdullah Uyaroğlu1 ORCID: 0000-0003-0440-2026 Meliha Çağla Sönmezer2 ORCID: 0000-0001-6529-5282 Gülçin Telli Dizman2 ORCID: 0000-0001-8195-3345 Nursel Çalık Başaran1 ORCID: 0000-0002-1290-6905 Sevilay Karahan3 ORCID: 0000-0002-8692-7266 Ömrüm Uzun2 ORCID: 0000-0003-4721-0139 Hacettepe University Faculty of Medicine, Department of Internal Medicine, Section of General Internal Medicine, Ankara, Turkey. 1 Hacettepe University Faculty of Medicine, Department of Clinical Microbiology and Infectious Disease, Ankara, Turkey. 2 Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey. ABSTRACT Objectives: In this study, we compared the clinical outcomes and effects of the treatments on laboratory parameters between patients who were treated with favipiravir (FAV) or hydroxychloroquine plus azithromycin (HCQ/AZ) for COVID-19 pneumonia in non-Intensive Care Unit (non-ICU) patients. Methods: We collected data of 260 moderate or severe COVID-19 patients hospitalized in COVID-19 wards between March 20, 2020, and September 30, 2020 retrospectively. We used propensity score matching to evaluate treatment effect on laboratory parameters of COVID-19 infection. Results: We compared 42 patients using FAV and 42 HCQ/AZ after propensity score matching. While there were statistical differences between the therapy groups in terms of transfer to ICU and/or exitus before matching (p=0.031), this was not significant after propensity analysis (p=0.250). Patients treated with FAV stayed in the hospital nearly one more day than HCQ/AZ group but the difference was not statistically significant (9.02 days vs 8.14 days, p=0.903). The levels of AST,ALT, and LDH increased at discharge in both groups, especially in the FAV group. Conclusions: FAV is not superior to HCQ/AZ in the treatment of COVID-19 infection in hospitalized patients with pneumonia. 3 Keywords: COVID-19, hydroxychloroquine, azithromycin, favipiravir, propensity-matched analysis Corresponding Author: Oğuz Abdullah Uyaroğlu Hacettepe University Faculty of Medicine, Department of Internal Medicine, Section of General Internal Medicine, Ankara, Turkey. E-mail: oguzuyaroglu@hotmail.com Received: 15 December 2021, Accepted: 25 January 2022, Published online: 10 March 2022 © 2022 Acta Medica. 73 Favipiravir Against Hydroxychloroquine Plus Azithromycin
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit